Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Autoimmune disease and C-Section: new study targets bleeding risks

NCT ID NCT06730919

Knowledge-focused Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 1,000 women with autoimmune diseases (like lupus) who had a C-section. Researchers wanted to find out how many had severe bleeding (postpartum hemorrhage) and what factors increased that risk. By analyzing medical records, they hope to identify high-risk patients and improve care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which women with autoimmune diseases are at highest risk for severe bleeding after C-section, leading to better prevention.
What could go wrong
This is a retrospective study, meaning it looks back at past records. It cannot prove cause and effect, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,000 people

The number who actually took part.

Started

Jun 2019

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All women with systemic autoimmune diseases who underwent cesarean delivery in Renji Hospital, School of Medicine, Shanghai Jiaotong University, The First Affiliated Hospital, Sun Yat-sen University, Women's hospital school of medicine zhejiang university，Obstetrics \& Gynecology Hospital of Fudan University，and Shanghai First Maternity and Infant Hospital between June 2019 and June 2024, and who met the inclusion criteria were eligible for the study.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Gestational period was ≥ 28 week; 2. Delivered by cesarean delivery; 3. With systemic autoimmune diseases (SLE, APS, SSc, SS,RA, UCTD) Exclusion Criteria: 1. Intrauterine fetal death 2. Hemorrhagic disease, significant prenatal bleeding 3. Missing clinical information

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antiphospholipid syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome autoimmune disease Postpartum Hemorrhage rheumatoid arthritis Sjogren syndrome systemic lupus erythematosus systemic sclerosis undifferentiated connective tissue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postpartum hemorrhage Systemic autoimmune diseases

Contacts and locations

Locations

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, China

  • Renji Hospital, Shanghai Jiaotong University, School of Medcine

    Shanghai, Shanghai Municipality, China

  • Shanghai First Maternity and Infant Hospital

    Shanghai, China

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, China

  • Women's hospital school of medicine zhejiang university

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.